Biosimilars

As Option Care Health preps its Q1 results, investors watch if it can seize market share from a retreating rival while navigating major biosimilar headwinds.

At AAN 2026, SK Life Science will present new cenobamate data and survey findings that expose a critical communication gap in epilepsy care.

President Trump's 100% tariff on imported drugs aims to secure the US supply chain, but the policy's success may hinge on unproven and unverified players.

A new tool reveals how a federal drug program may be inflating healthcare costs for businesses, intensifying the debate over transparency and reform.

Biotech veteran Dr. Vince O'Neill joins Mosaic Therapeutics to spearhead its synergistic precision oncology pipeline, aiming to transform cancer treatment.

Parnell’s nixiFLOR, the first generic of Resflor Gold®, offers a cost-effective new weapon for ranchers battling Bovine Respiratory Disease.

With its lead drug for a rare pediatric liver disease entering late-stage trials, NorthSea Therapeutics adds a veteran drug developer to its board.

Landmark study results show a new drug-coated balloon significantly improves outcomes for Peripheral Artery Disease, heralding a major shift in treatment.

Biocon merges its biosimilar and generics units, appointing 30-year veteran Shreehas Tambe as CEO to forge a new globally-scaled biopharma enterprise.

With critical data due in 2026 and a leaner financial strategy, Zentalis is advancing its targeted therapy for a hard-to-treat ovarian cancer.

The FDA has clarified its rules for desiccated thyroid extract (DTE), providing relief for patients and a new path forward for manufacturers like Acella.

Cingulate Inc. faces a critical FDA decision for its novel ADHD drug, but manufacturing queries and a tight cash runway create a high-stakes countdown.

A landmark CHF 83.5M deal brings corticorelin, a promising steroid-sparing therapy for brain cancer patients, to Japan, offering a new frontier in care.

Amid fierce competition, Triangle Insights Group hires a seasoned expert to guide clients through the complex world of drug pricing and market access.

Tenax Therapeutics achieves a major clinical trial goal, moving its promising drug TNX-103 closer to becoming the first approved therapy for a deadly heart condition.

Telehealth firm Direct Meds offers cheap GLP-1 drugs, but an FDA warning for "false claims" and the end of drug shortages cast a long shadow on its model.

AEON Biopharma hires a seasoned CFO to navigate FDA trials and financial hurdles as it aims to launch its BOTOX biosimilar into a lucrative market.

A new drug for Raynaud's phenomenon in scleroderma patients significantly boosts attack-free days, offering hope despite missing its primary trial goal.

Cordis presents pivotal 12-month data for its innovative SELUTION SLR drug-eluting balloon, a device that could change how doctors treat clogged arteries.

FDA approves Glenmark's generic inhaler with 180-day exclusivity, promising lower costs for millions and disrupting a major respiratory drug market.